Compare Koninklijke Philips NV (PHG) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs ResMed Inc. — how do they compare? Koninklijke Philips NV trades at $26.3 (market cap $25.89B), while ResMed Inc. trades at $193.21 (market cap $28.40B). The key difference: Koninklijke Philips NV and ResMed Inc. are close in size by market cap, and Koninklijke Philips NV pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| PHG | RMD | |
|---|---|---|
Market Cap | $25.89B | $28.40B |
Sector | Health | Health |
52-Week High | $32.91 | $293.73 |
52-Week Low | $25.02 | $182.82 |
Enterprise Value | $32.18B | $27.58B |
Dividend Yield | 3.81% | 1.23% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
